ArticleTherapeutic advances in medical oncology2022

GUIDE: a randomised non-comparative phase II trial of biomarker-driven intermittent docetaxel

Ciara Conduit et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.